Detalles de la búsqueda
1.
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Breast Cancer Res Treat
; 140(2): 253-62, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23852223
2.
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Breast Cancer Res
; 14(2): R57, 2012 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22475046
3.
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
Breast Cancer Res
; 14(2): R46, 2012 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417870
4.
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Breast Cancer Res
; 12(5): R76, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20920193
5.
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat
; 119(2): 315-23, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19247830
6.
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Breast Cancer Res Treat
; 123(3): 829-36, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20697803
7.
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res Treat
; 116(1): 53-68, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18592370
8.
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Mol Cancer Ther
; 6(9): 2458-67, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17876043
9.
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
Cancer Lett
; 247(2): 259-65, 2007 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-16777318
10.
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Clin Cancer Res
; 12(3 Pt 2): 1024s-1030s, 2006 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16467120
11.
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
J Clin Oncol
; 23(11): 2477-92, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15767642
12.
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Clin Cancer Res
; 11(2 Pt 2): 951s-8s, 2005 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15701892
13.
Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Cancer Res
; 63(19): 6516-22, 2003 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14559845
14.
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
J Clin Oncol
; 21(13): 2492-9, 2003 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12829668
15.
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
J Clin Oncol
; 20(4): 1026-35, 2002 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11844826
16.
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
Clin Cancer Res
; 9(7): 2651-6, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12855643
17.
Who would have thought a single Ki67 measurement would predict long-term outcome?
Breast Cancer Res
; 11 Suppl 3: S15, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-20030866
18.
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Cancer Epidemiol Biomarkers Prev
; 11(7): 614-21, 2002 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12101108
19.
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Clin Cancer Res
; 19(10): 2775-86, 2013 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23493347
20.
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
J Natl Cancer Inst
; 104(6): 452-60, 2012 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22395643